Amgen: profitable every year.
- Industry
- Biological Products,
- Headquarters
- United States
- Ticker
- AMGN (Nasdaq)
- Sources
- SEC filings (1994–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- November 2, 2026
- One decision on record. Stratrix has verified one of Amgen's big decisions, each with what happened next.
- Profitable every year. Amgen made money in each of its last ten fiscal years, from $2 billion (2017) to $8.4 billion (2018).
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $23 billion | $7.7 billion | |
| 2017 | $22.8 billion | $2 billion | |
| 2018 | $23.7 billion | $8.4 billion | |
| 2019 | $23.4 billion | $7.8 billion | |
| 2020 | $25.4 billion | $7.3 billion | |
| 2021 | $26 billion | $5.9 billion | |
| 2022 | $26.3 billion | $6.6 billion | |
| 2023 | $28.2 billion | $6.7 billion | |
| 2024 | $33.4 billion | $4.1 billion | |
| 2025 | $36.8 billion | $7.7 billion |
As reported in its annual filings. Losses in red.
Stratrix Decision Cases
Has Amgen had layoffs?
Job cuts, severance and restructuring
Company ran a restructuring plan that was started and substantially finished in 2023, with related expenses recorded in other operating expenses.
“Other operating expenses for 2023 primarily consisted of a net IPR&D intangible asset impairment charge for AMG 340 and expenses related to our restructuring plan that were both initiated and substantially completed in 2023.” 10-K for 2024
Company incurred expenses tied to cost-savings initiatives in 2024, recorded in other operating expenses.
“Other operating expenses for 2024 primarily consisted of impairment charges associated with IPR&D intangible assets related to our Teneobio acquisition in 2021 and expenses related to cost-savings initiatives incurred in 2024.” 10-K for 2024
Company recorded acquisition costs for the Horizon closing, including severance and other employee-related expenses.
“During the three months ended December 31, 2023, the Company incurred approximately $ 487 million of acquisition costs related to the closing of our Horizon acquisition, consisting of $ 167 million for share-based payments to settle non-vested equity awards attributable to post-combination services, severance and other employee-related expenses and $ 320 million for transaction costs.” 10-K for 2024
Amgen reported expenses for cost-savings initiatives in 2024 and for a restructuring plan that was started and substantially completed in 2023, both included in other operating expenses.
“Other operating expenses for 2023 included a net IPR&D intangible asset impairment charge for AMG 340 and expenses related to our restructuring plan that were both initiated and substantially completed in 2023.” 10-K for 2025
| Fiscal year ended | Restructuring charges | Cash paid for restructuring |
|---|---|---|
| 2016-12-31 | $19 million | $117 million |
| 2017-12-31 | $79 million | $31 million |
| 2023-12-31 | $267 million | — |
Amgen has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
What has Amgen acquired?
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Horizon Therapeutics plc“In October 2023, we completed our acquisition of Horizon for $116.50 per share in cash, representing a total transaction price of $27.8 billion.” 10-K for 2023 | acquisition | In October 2023 | $116.50 per share in cash, representing a total transaction price of $27.8 billion |
Bergamo subsidiary“(2) Consists of product sales of our non-principal products, as well as sales prior to the divestiture of our Bergamo and Gensenta subsidiaries in the second quarter of 2023 and fourth quarter of 2022, respectively.” 10-K for 2023 | divestiture | second quarter of 2023 | — |
Gensenta subsidiary“(2) Consists of product sales of our non-principal products, as well as sales prior to the divestiture of our Bergamo and Gensenta subsidiaries in the second quarter of 2023 and fourth quarter of 2022, respectively.” 10-K for 2023 | divestiture | fourth quarter of 2022 | — |
ChemoCentryx“Cash used in investing activities during 2022 was primarily due to our $3.8 billion purchase of ChemoCentryx and net cash outflows related to marketable securities of $1.4 billion.” 10-K for 2023 | acquisition | — | $3.8 billion purchase of ChemoCentryx |
Teneobio and Five Prime“Cash provided by investing activities during 2021 was primarily due to net cash inflows related to marketable securities of $4.3 billion, partially offset by cash used in the acquisitions of Teneobio and Five Prime of $2.5 billion.” 10-K for 2023 | acquisition | 2021 | $2.5 billion |
Otezla (acquired from Bristol Myers Squibb Company)“Otezla was acquired from Bristol Myers Squibb Company in November 2019 after their acquisition of Celgene.” 10-K for 2023 | acquisition | November 2019 | — |
Otezla (from Bristol-Myers Squibb Company)“Otezla was acquired from Bristol-Myers Squibb Company in November 2019 after its acquisition of Celgene Corporation.” 10-K for 2024 | acquisition | November 2019 | — |
BeiGene, Ltd.“In January 2020, we acquired an equity stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China.” 10-K for 2024 | acquisition | January 2020 | approximately $2.8 billion in cash |
Gensenta“Other operating expenses for 2022 primarily consisted of a loss on the divestiture of Gensenta.” 10-K for 2024 | divestiture | — | — |
Horizon“(1) TEPEZZA and KRYSTEXXA were acquired from our Horizon acquisition on October 6, 2023, and include product sales in the periods after the acquisition date.” 10-K for 2025 | acquisition | October 6, 2023 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2016-12-31 | $0 | $0 |
| 2017-12-31 | $19 million | $0 |
| 2018-12-31 | −$195 million | $6 million |
| 2019-12-31 | $13.62 billion | $26 million |
| 2020-12-31 | $0 | $0 |
| 2021-12-31 | $2.53 billion | $251 million |
| 2022-12-31 | $3.84 billion | $651 million |
| 2023-12-31 | $26.99 billion | — |
| 2024-12-31 | $0 | — |
| 2025-12-31 | $53 million | — |
Deal filings since 2016
- 2026-02-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-10-06 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2023-03-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-03-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-02-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-01-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-12-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-12-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-08-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-08-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-02-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-02-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-01-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-08-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-07-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-06-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-04-16 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2021-03-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-08-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-02-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-12-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-11-21 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2019-10-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-10-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-08-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-11-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-05-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-04-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-01-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-08-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-06-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-03-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-02-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Who are Amgen's competitors?
Who Amgen names
| Company | Named in |
|---|---|
| Novartis AG | 2025 |
| Regeneron Pharmaceuticals, Inc. | 2025 |
In its own words
Novartis AG, Regeneron Pharmaceuticals, Inc.
“Product Territory Competitor-marketed product Competitors Prolia U.S., Europe & Asia Pacific Bisphosphonates, including generics Various U.S., Europe & Asia Pacific Denosumab biosimilars Various Repatha U.S., Europe & Asia Pacific LEQVIO ® Novartis AG U.S., Europe & Asia Pacific PRALUENT ® Regeneron Pharmaceuticals, Inc.” 10-K for 2025
Who names Amgen
Companies whose own annual reports name Amgen as a competitor.
“This segment’s major competitors, including Viatris Inc. (Viatris), Jazz Pharmaceuticals plc (Jazz), Takeda Pharmaceutical Company Limited and Amgen, Inc., among others, vary depending on therapeutic and product category, dosage strength and drug-delivery systems, among other factors.” 10-K for 2024
“This segment’s major competitors, including Viatris Inc. (Viatris), Jazz Pharmaceuticals plc (Jazz), Takeda Pharmaceutical Company Limited and Amgen, Inc., among others, vary depending on therapeutic and product category, dosage strength and drug-delivery systems, among other factors.” 10-K for 2023
“There are also a number of products for the treatment of first and second line SCLC in various phases of development, including Amgen Inc.’s tarlatamab, which was approved for second line use in the U.S. in May 2024.” 10-K for 2025
What are Amgen's subsidiaries?
Subsidiaries it lists
| Subsidiary | Jurisdiction |
|---|---|
| Amgen (Europe) GmbH | Switzerland |
| Amgen Canada Inc. | Canada |
| Amgen Fremont Inc. | Delaware |
| Amgen Global Finance B.V. | Netherlands |
| Amgen Global Technology Unlimited Company | Ireland |
| Amgen GmbH Germany | Germany |
| Amgen Ilaç Ticaret Limited Şirketi | Türkiye |
| Amgen International Holdings Inc. | Delaware |
| Amgen K.K. | Japan |
| Amgen K-A, Inc. | Delaware |
| Amgen Manufacturing Limited LLC | Puerto Rico |
| Amgen Rare Disease Holdings Inc. | Delaware |
| Amgen Research (Munich) GmbH | Germany |
| Amgen S.A.S. | France |
| Amgen S.p.A. | Italy |
| Amgen SF, LLC | Delaware |
| Amgen Singapore Holding Pte. Ltd. | Singapore |
| Amgen Singapore Manufacturing Pte. Ltd. | Singapore |
| Amgen Technology (Ireland) Unlimited Company | Ireland |
| Amgen Technology, Limited | Bermuda |
| Amgen USA Inc. | Delaware |
| Amgen Worldwide Holdings B.V. | Netherlands |
| Amgen, S.A. | Spain |
| BioVex LLC | Delaware |
| ChemoCentryx, Inc. | Delaware |
| Five Prime Therapeutics, Inc. | Delaware |
| Horizon Therapeutics Finance S.à.r.l | Luxembourg |
| Horizon Therapeutics Holdings Limited | Ireland |
| Horizon Therapeutics Ireland DAC | Ireland |
| Horizon Therapeutics Limited | Ireland |
| Horizon Therapeutics Services LLC | Delaware |
| Horizon Therapeutics U.S. Holding LLC | Delaware |
| Horizon Therapeutics USA, Inc. | Delaware |
| HZNP Finance Limited | Bermuda |
| Immunex Corporation | Washington |
| Immunex Rhode Island Corporation | Delaware |
| Onyx Pharmaceuticals, Inc. | Delaware |
| Onyx Therapeutics, Inc. | Delaware |
| Pillartree Limited | Ireland |
| Saga Investments Coöperatief U.A. | Netherlands |
| TeneoBio, Inc. | Delaware |
| Viela Bio, Inc. | Delaware |
From Exhibit 21 of the 10-K for 2025. Companies must list their significant subsidiaries there and may leave out smaller ones, so this is the company’s own list, not every entity it owns.
Layoffs, acquisitions, competitors and subsidiaries are read from Amgen’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023), as of 2026-02-13.
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 55 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (19 with market data).
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 264 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.
More from Stratrix
The Business Model Wizard
Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.
Free · about twelve minutesBuild your Model Thesis →Test a decision, free
Set a live decision against the companies that made it before you.
AcquisitionsThe Distance TestDivestituresThe Divestiture TestDiversificationThe Diversification TestMake or buyThe Make-or-Buy TestStratrix Team
Every Casebook, three Strategy Packs a seat each year and Ask Stratrix, for teams that face these decisions all year.
$1,999 a year · $499 a seatWhat is included →New analyses, by email
The defining moves in business, and what they teach, as they publish.